Spruce Biosciences launches site for planned TA-ERT Sanfilippo B confirmatory trial in Q4 2026

• Spruce Biosciences launched MPS3BStudy.com to register interest for planned U.S. access and trial programs for tralesinidase alfa.
• No study results were presented; both the Expanded Access Program and TrAnsform confirmatory study are slated to start as early as Q4 2026.
• Expanded Access Program targets children with attenuated or severe Sanfilippo type B who cannot join the confirmatory study; about 10 participants.
• TrAnsform is a randomized controlled study in severe disease, comparing investigational therapy versus standard care; about 14 participants.
• Programs aim to evaluate safety and whether treatment can preserve cognitive function, supporting a planned FDA review pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260826942671) on August 26, 2026, and is solely responsible for the information contained therein.